NCT04558385

Brief Summary

This study investigate the kinetics of IgG responses to both N and S proteins in the subjects who suffered from COVID 19 and then had recovered.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
275

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2020

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 20, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 22, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2021

Completed
Last Updated

April 1, 2021

Status Verified

March 1, 2021

Enrollment Period

9 months

First QC Date

September 20, 2020

Last Update Submit

March 30, 2021

Conditions

Covid19

Outcome Measures

Primary Outcomes (1)

  • IgG SARS CoV2

    Presence or absence of SARV CoV2 IgG antibodies

    5 months

Interventions

IgG SARS CoV2DIAGNOSTIC_TEST

IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

population who have suffered from COVID 19, whose disease was either confirmed by PCR or clinically and then recovered

You may qualify if:

  • Subjects recovered from COVID 19 confirmed on PCR or clinically

You may not qualify if:

  • subjects who have not been confirmed suffering from COVID 19 by PCR or clinically

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lahore General Hospital

Lahore, Punjab Province, 54500, Pakistan

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Amina Asif, MPhilMicro

    LahoreGeneralHospital.Lahore

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

September 20, 2020

First Posted

September 22, 2020

Study Start

July 1, 2020

Primary Completion

March 31, 2021

Study Completion

March 31, 2021

Last Updated

April 1, 2021

Record last verified: 2021-03

Locations

PA(1)